Recursion gains FDA alignment on phase 3 trial design for FAP
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
What's breaking now, across thousands of outlets.
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
Experts said the results are encouraging, but that more research is needed before the drug is offered to patients.
The nights are drawing in, the temperature is dropping, festive overindulgence is on the horizon and it’s easy to get run down.
The administration’s expansion of traditional healing for Native Americans comes as it shrinks Medicaid in other ways, including through restrictions that will affect access to care for an estimated…